Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Milman, C. B. Svendsen, H. J. Moller (Copenhagen, Aarhus, Denmark). Can soluble CD-163 be related to disease activity in pulmonary sarcoidosis?. Eur Respir J 2010; 36: Suppl. 54, 842

Member's Comments

No comment yet.

Related content which might interest you: IL-6 and IL-8 in stable and exacerbated IPF patients and their association to outcome Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Enhanced expression of IL-18 receptor but not soluble form of IL18R in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011 Potential association between pulmonary hypertension in COPD and monocyte chemoattractant protein (MCP)-1 Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Tumor-associated antigens in acute exacerbation of idiopathic pulmonary fibrosis: Associations with disease activity Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 The markers of inflammatory process activity and fybrogenesis activity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis Source: Eur Respir J 2002; 19: 439-446 Year: 2002 Interleukin-18 production and pulmonary function in COPD Source: Eur Respir J 2008; 31: 287-297 Year: 2008 COPD is associated with reduced pulmonary interstitial expression of pentraxin-3 Source: Eur Respir J 2012; 39: 830-838 Year: 2012 Endotrophin is related to disease progression in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 T-bet is augmented during the pathogenesis of pulmonary sarcoidosis Source: Annual Congress 2009 - Cell biology of lung disease Year: 2009 IL-36? – a key mediator of neutrophilic inflammation in chronic obstructive pulmonary disease Source: Virtual Congress 2021 – New insights into the airway immunology of lung disease Year: 2021 Expression profile of Th1/Th2 transcription factors T-bet and GATA-3 in sarcoidosis, idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease Year: 2010 VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis Source: Eur Respir J 2011; 38: 1355-1360 Year: 2011 Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease Source: Eur Respir J, 53 (5) 1802182; 10.1183/13993003.02182-2018 Year: 2019 Role of systemic inflammation mediated by IL-6 and TNF-alpha cytokines in chronic obstructive pulmonary disease and its progression: A three year follow up study Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Longitudinal serological assessment of neutrophil activity is related to disease progression in idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 The role anti-inflammatory cytokines in pathogenesis professional occupetional pulmonary disease Source: Eur Respir J 2003; 22: Suppl. 45, 122s Year: 2003 Procoagulant and antifibrynolitic activities strongly correlate with fibrosis and tissue turn-over markers in patients with active idiopathic pulmonary fibrosis and hypersensitivity pneumonitis Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease Year: 2008